We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
DVA benefits from its integrated kidney care model and international expansion.
DaVita is expanding across Europe and Asia, adding centers via acquisitions and partnerships.
DVA faces margin pressure risk as it shifts from commercial insurance to Medicare and Medicaid.
DaVita Inc. (DVA - Free Report) has been gaining from its business model. The optimism, led by a decent third-quarter 2025 performance and the overseas growth, is expected to contribute further. However, concerns regarding its dependence on commercial payers persist.
So far this year, this Zacks Rank #3 (Hold) stock has lost 24.9% against the industry's 11.2% growth and the S&P 500's 12.9% increase.
The renowned global comprehensive kidney care provider has a market capitalization of $7.39 billion. The company projects 12.6% growth for the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 0.3%.
Image Source: Zacks Investment Research
Upsides
Business Model: DaVita’s patient-centric model integrates a broad kidney care platform to expand patient choice across care settings and treatment modalities. As value-based arrangements gain traction in kidney care, collaboration among nephrologists, providers and transplant programs is deepening, enabling better care coordination and earlier clinical intervention. DaVita’s Integrated Kidney Care business actively participates in CMMI’s Comprehensive Kidney Care Contracting model, which focuses on managing late-stage CKD and ESKD patients to slow disease progression, increase home dialysis adoption and encourage transplants.
The company also operates dialysis centers through joint ventures in which it typically holds controlling stakes, while partners such as nephrologists, hospitals and other healthcare providers own minority interests. Many of DaVita’s outpatient centers support home hemodialysis and peritoneal dialysis, helping eligible patients receive treatment at home.
Overseas Growth: DaVita is steadily expanding in the international markets. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances and acquisitions of dialysis centers. These are expected to help DaVita deliver more efficient patient care.
Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships. In 2025, management expects operating growth in the company’s international business as it continues expansion in international markets.
As of Sept. 30, 2025, DaVita provided dialysis services to around 293,200 patients at 3,247 outpatient dialysis centers, of which 2,662 were U.S. centers while 585 were located across 14 other countries. During the third quarter of 2025, the company opened three dialysis centers in the United States. It also acquired 58 dialysis centers outside the United States in the same period.
Mixed Q3 Results: DaVita ended the third quarter of 2025 with mixed results. The uptick in the company’s top line and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the third quarter on a sequential basis and solid revenues from dialysis patient service were encouraging. The opening of dialysis centers within the United States and the acquisition of centers overseas were promising.
However, the year-over-year decline in the bottom line and normalized non-acquired treatment was disappointing.
Downsides
Dependence on Commercial Payers: DaVita generates a meaningful share of dialysis and lab revenues, and most of its profits, from commercially insured patients, but this mix is under pressure. Rising unemployment could accelerate shifts from commercial plans to government coverage, and the share of non-government reimbursed treatments has already been declining.
With a large portion of patients already covered by Medicare or Medicaid, further growth in Medicare Advantage enrolment could compress margins, as lower government reimbursement rates may strain profitability and potentially lead to dialysis center closures.
Estimate Trend
DaVita is witnessing a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings per share has remained stable at $10.70.
The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pegged at $3.53 billion, indicating a 6.9% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $3.24 per share, implying a 44.6% year-over-year decline.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Key Takeaways
DaVita Inc. (DVA - Free Report) has been gaining from its business model. The optimism, led by a decent third-quarter 2025 performance and the overseas growth, is expected to contribute further. However, concerns regarding its dependence on commercial payers persist.
So far this year, this Zacks Rank #3 (Hold) stock has lost 24.9% against the industry's 11.2% growth and the S&P 500's 12.9% increase.
The renowned global comprehensive kidney care provider has a market capitalization of $7.39 billion. The company projects 12.6% growth for the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 0.3%.
Image Source: Zacks Investment Research
Upsides
Business Model: DaVita’s patient-centric model integrates a broad kidney care platform to expand patient choice across care settings and treatment modalities. As value-based arrangements gain traction in kidney care, collaboration among nephrologists, providers and transplant programs is deepening, enabling better care coordination and earlier clinical intervention. DaVita’s Integrated Kidney Care business actively participates in CMMI’s Comprehensive Kidney Care Contracting model, which focuses on managing late-stage CKD and ESKD patients to slow disease progression, increase home dialysis adoption and encourage transplants.
The company also operates dialysis centers through joint ventures in which it typically holds controlling stakes, while partners such as nephrologists, hospitals and other healthcare providers own minority interests. Many of DaVita’s outpatient centers support home hemodialysis and peritoneal dialysis, helping eligible patients receive treatment at home.
Overseas Growth: DaVita is steadily expanding in the international markets. In the past few years, the company has strengthened its position in the emerging and developing markets of Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal and Saudi Arabia through strategic alliances and acquisitions of dialysis centers. These are expected to help DaVita deliver more efficient patient care.
Currently, DaVita is seeking to expand in major European and Asian countries via acquisitions and partnerships. In 2025, management expects operating growth in the company’s international business as it continues expansion in international markets.
As of Sept. 30, 2025, DaVita provided dialysis services to around 293,200 patients at 3,247 outpatient dialysis centers, of which 2,662 were U.S. centers while 585 were located across 14 other countries. During the third quarter of 2025, the company opened three dialysis centers in the United States. It also acquired 58 dialysis centers outside the United States in the same period.
Mixed Q3 Results: DaVita ended the third quarter of 2025 with mixed results. The uptick in the company’s top line and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the third quarter on a sequential basis and solid revenues from dialysis patient service were encouraging. The opening of dialysis centers within the United States and the acquisition of centers overseas were promising.
However, the year-over-year decline in the bottom line and normalized non-acquired treatment was disappointing.
Downsides
Dependence on Commercial Payers: DaVita generates a meaningful share of dialysis and lab revenues, and most of its profits, from commercially insured patients, but this mix is under pressure. Rising unemployment could accelerate shifts from commercial plans to government coverage, and the share of non-government reimbursed treatments has already been declining.
With a large portion of patients already covered by Medicare or Medicaid, further growth in Medicare Advantage enrolment could compress margins, as lower government reimbursement rates may strain profitability and potentially lead to dialysis center closures.
Estimate Trend
DaVita is witnessing a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for earnings per share has remained stable at $10.70.
The Zacks Consensus Estimate for the company’s fourth-quarter 2025 revenues is pegged at $3.53 billion, indicating a 6.9% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $3.24 per share, implying a 44.6% year-over-year decline.
Stocks to Consider
Some better-ranked stocks in the broader medical space are IDEXX Laboratories (IDXX - Free Report) , Boston Scientific (BSX - Free Report) and STERIS (STE - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.
Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.